Cuprina Holdings Falls 22% After 112% Rally — Here's Why CUPR Stock Is Trending

Cuprina Holdings (NASDAQ: CUPR) whipsawed traders with a 111.84% intraday surge to $8.41 followed by a 22.47% after-hours decline to $6.52. The catalyst: FDA 510(k) clearance for MEDIFLY Maggots, a maggot debridement therapy for non-healing wounds.

The Singapore-based biomedical company now holds the first FDA clearance for a maggot debridement product using the Lucilia cuprina species. This approval gives Cuprina commercial rights to both maggot species currently used in debridement therapy, positioning the company as the sole provider with access to both treatment options in a niche medical market.

The dramatic volatility reflects classic small-cap biotech price action on binary regulatory catalysts. The initial 112% rally pushed CUPR into momentum-trader territory before profit-taking erased nearly a quarter of the gains in extended trading. The approval itself marks commercial viability for a product that addresses chronic wound care, though the addressable market size and revenue projections were not disclosed.